Bridget Mulvany-Robbins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bridget Mulvany-Robbins has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Grayson Beecher
University of Alberta
4 shared publications Andrea J. Boon
Department of Physical Medicine and Rehabilitation Mayo Clinic Rochester Minnesota USA
1 shared publication- Brendan Nicholas Putko
Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada
1 shared publication Brendan Putko
Division of Neurology, Department of Medicine, University of Alberta, 7-125 Clinical Sciences Building 11350 83rd Avenue NW, Edmonton, AB, Canada T6G 2G3
1 shared publicationCecile Phan
Division of Neurology, Department of Medicine, University of Alberta, 7-125 Clinical Sciences Building 11350 83rd Avenue NW, Edmonton, AB, Canada T6G 2G3
1 shared publicationElise D. Hansen
Cumming School of Medicine University of Calgary Calgary Alberta Canada
1 shared publication
Latest Publications
- 4 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (6) , 368
Tocilizumab for severe immune checkpoint inhibitor myopathy–myocarditis: acute and long-term outcomes
Background Immune checkpoint inhibitor (ICI)-myopathy–myocarditis is an immune-related adverse event, with high mortality despite first-line immunosuppression. Emerging data suggest upregulation of the interleukin-6 (IL-6) pathway in ICI-myopathy, raising interest in IL-6 receptor blockade as escalation therapy. We aimed to characterize acute and long-term functional and oncologic outcomes for severe ICI-myopathy–myocarditis, with focus on those treated with tocilizumab after failure of first-line therapy. Methods We performed a retrospective cohort study of patients admitted with severe (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or 4) ICI-myopathy–myocarditis managed at a Canadian tertiary referral center. Clinical characteristics, investigations, treatment, and functional and long-term cancer outcomes were summarized. Patients were stratified by treatment with tocilizumab after first-line therapy. Primary outcomes were in-hospital mortality and acute-phase survival. Secondary outcomes included functional status at last follow-up, final CTCAE grade, and oncologic response. Results Eleven patients were identified. Eight patients received second-line tocilizumab at a median of 13 days after admission; weakness improved in all, but only 4 survived hospitalization. Among acute-phase survivors, median follow-up was 8.1 months, with final median CTCAE grade of 1. Limb strength normalized before oculobulbar weakness. Most survivors demonstrated partial oncologic response, followed by later disease progression at a median 8 months. No patients were rechallenged with ICI therapy. Discussion In severe ICI-myopathy–myocarditis refractory to first-line therapy, escalation with IL-6 receptor blockade was temporally associated with limb muscle strength improvement and favorable long-term functional outcomes among survivors. These findings support further evaluation of tocilizumab as second-line therapy in this high-risk population.
- 4 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (6) , 368
Tocilizumab for severe immune checkpoint inhibitor myopathy–myocarditis: acute and long-term outcomes
Background Immune checkpoint inhibitor (ICI)-myopathy–myocarditis is an immune-related adverse event, with high mortality despite first-line immunosuppression. Emerging data suggest upregulation of the interleukin-6 (IL-6) pathway in ICI-myopathy, raising interest in IL-6 receptor blockade as escalation therapy. We aimed to characterize acute and long-term functional and oncologic outcomes for severe ICI-myopathy–myocarditis, with focus on those treated with tocilizumab after failure of first-line therapy. Methods We performed a retrospective cohort study of patients admitted with severe (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or 4) ICI-myopathy–myocarditis managed at a Canadian tertiary referral center. Clinical characteristics, investigations, treatment, and functional and long-term cancer outcomes were summarized. Patients were stratified by treatment with tocilizumab after first-line therapy. Primary outcomes were in-hospital mortality and acute-phase survival. Secondary outcomes included functional status at last follow-up, final CTCAE grade, and oncologic response. Results Eleven patients were identified. Eight patients received second-line tocilizumab at a median of 13 days after admission; weakness improved in all, but only 4 survived hospitalization. Among acute-phase survivors, median follow-up was 8.1 months, with final median CTCAE grade of 1. Limb strength normalized before oculobulbar weakness. Most survivors demonstrated partial oncologic response, followed by later disease progression at a median 8 months. No patients were rechallenged with ICI therapy. Discussion In severe ICI-myopathy–myocarditis refractory to first-line therapy, escalation with IL-6 receptor blockade was temporally associated with limb muscle strength improvement and favorable long-term functional outcomes among survivors. These findings support further evaluation of tocilizumab as second-line therapy in this high-risk population.
- 1 December 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (2) , 239-241
Bilateral hemidiaphragm atrophy and electrical myotonia in anti‐muscle specific tyrosine kinase myasthenia gravis
- 1 December 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (2) , 239-241
Bilateral hemidiaphragm atrophy and electrical myotonia in anti‐muscle specific tyrosine kinase myasthenia gravis
- Open Access
- 25 October 2023
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 51 (6) , 871-873
Double trouble: Kennedy Disease and Immune-Mediated Necrotizing Myopathy in a Cree Male
- 25 October 2023
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 51 (6) , 871-873
Open AccessDouble trouble: Kennedy Disease and Immune-Mediated Necrotizing Myopathy in a Cree Male
- 31 May 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33 (7) , 546-550
Novel p.Asp27Glu ACTA1 variant features congenital myopathy with finger flexor weakness, cardiomyopathy, and cardiac conduction defects
- 31 May 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33 (7) , 546-550
Novel p.Asp27Glu ACTA1 variant features congenital myopathy with finger flexor weakness, cardiomyopathy, and cardiac conduction defects